Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

169 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Molecular genetics of head and neck squamous cell carcinoma.
Saada-Bouzid E, Peyrade F, Guigay J. Saada-Bouzid E, et al. Among authors: peyrade f. Curr Opin Oncol. 2019 May;31(3):131-137. doi: 10.1097/CCO.0000000000000536. Curr Opin Oncol. 2019. PMID: 30893149 Review.
Approach to the Patient with Recurrent/Metastatic Disease.
Guigay J, Sâada-Bouzid E, Peyrade F, Michel C. Guigay J, et al. Among authors: peyrade f. Curr Treat Options Oncol. 2019 Jun 25;20(8):65. doi: 10.1007/s11864-019-0664-z. Curr Treat Options Oncol. 2019. PMID: 31240480 Review.
Cetuximab combined with paclitaxel or paclitaxel alone for patients with recurrent or metastatic head and neck squamous cell carcinoma progressing after EXTREME.
Chevalier T, Daste A, Saada-Bouzid E, Loundou A, Peyraud F, Lambert T, Le Tourneau C, Peyrade F, Dupuis C, Alfonsi M, Fayette J, Reure J, Huguet F, Fakhry N, Toullec C, Salas S. Chevalier T, et al. Among authors: peyrade f. Cancer Med. 2021 Jun;10(12):3952-3963. doi: 10.1002/cam4.3953. Epub 2021 May 25. Cancer Med. 2021. PMID: 34080776 Free PMC article.
Observational, prospective, phase 4 study in patients with first-line recurrent and/or metastatic squamous cell carcinoma of the head and neck treated with cetuximab and platinum-based therapy: DIRECT.
Guigay J, Chamorey E, Lefebvre G, Rotarski M, Wagner JP, Blot E, Alfonsi M, Seronde A, Schulten J, Peyrade F, Le Tourneau C. Guigay J, et al. Among authors: peyrade f. Cancer Rep (Hoboken). 2022 Feb;5(2):e1467. doi: 10.1002/cnr2.1467. Epub 2021 Jun 22. Cancer Rep (Hoboken). 2022. PMID: 34156166 Free PMC article. Clinical Trial.
Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial.
Guigay J, Aupérin A, Fayette J, Saada-Bouzid E, Lafond C, Taberna M, Geoffrois L, Martin L, Capitain O, Cupissol D, Castanie H, Vansteene D, Schafhausen P, Johnson A, Even C, Sire C, Duplomb S, Evrard C, Delord JP, Laguerre B, Zanetta S, Chevassus-Clément C, Fraslin A, Louat F, Sinigaglia L, Keilholz U, Bourhis J, Mesia R; GORTEC; AIO; TTCC, and UniCancer Head and Neck groups. Guigay J, et al. Lancet Oncol. 2021 Apr;22(4):463-475. doi: 10.1016/S1470-2045(20)30755-5. Epub 2021 Mar 5. Lancet Oncol. 2021. PMID: 33684370 Clinical Trial.
169 results